This Review is part of an ongoing series on Mitochondria in Health and Disease, which includes the following articles:
Mitochondrial Control of Cellular Life, Stress, and Death [Circ Res. 2012;111:1198-1207]

Mitochondria as a Drug Target in Ischemic Heart Disease and Cardiomyopathy

Physiological Roles of the Permeability Transition Pore
Exercising Mitochondria for Cardioprotection
Mitochondria and Endothelial Function
Mitochondria and ROS Generation

Guido Kroemer & Lorenzo Galluzzi, Guest Editors

Mitochondria as a Drug Target in Ischemic Heart Disease and Cardiomyopathy

Andrew M. Walters, George A. Porter Jr, Paul S. Brookes

Abstract: Ischemic heart disease is a significant cause of morbidity and mortality in Western society. Although interventions, such as thrombolysis and percutaneous coronary intervention (PCI), have proven efficacious in ischemia and reperfusion injury, the underlying pathological process of ischemic heart disease, laboratory studies suggest further protection is possible, and an expansive research effort is aimed at bringing new therapeutic options to the clinic. Mitochondrial dysfunction plays a key role in the pathogenesis of ischemia and reperfusion injury and cardiomyopathy. However, despite promising mitochondria-targeted drugs emerging from the laboratory, very few have successfully completed clinical trials. As such, the mitochondrion is a potential untapped target for new ischemic heart disease and cardiomyopathy therapies. Notably, there are a number of overlapping therapies for both these diseases, and as such novel therapeutic options for one condition may find use in the other. This review summarizes efforts to date in targeting mitochondria for ischemic heart disease and cardiomyopathy therapy and outlines emerging drug targets in this field. (Circ Res. 2012;111:1222-1236.)

Key Words: bioenergetics ■ clinical trial ■ ischemia ■ permeability transition pore ■ reperfusion ■ therapeutics

Ischemic heart disease (IHD) is a significant cause of morbidity and mortality in Western society.1 Although interventions, such as thrombolysis and percutaneous coronary intervention (PCI), have proven efficacious in ischemia and reperfusion (IR) injury, the underlying pathological process of IHD, laboratory studies suggest further protection is possible, and an expansive research effort is aimed at bringing new therapeutic options to the clinic. Mitochondrial dysfunction plays a key role in the pathogenesis of IR injury and cardiomyopathy (CM).2,3 However, despite promising mitochondria-targeted drugs emerging from the laboratory, very few have successfully completed clinical trials. As such, the mitochondrion is a potential untapped target for new IHD and CM therapies. Notably, there are a number of overlapping therapies for both these diseases, and as such novel therapeutic options for one condition may find use in the other. This review summarizes efforts to date in targeting mitochondria for IHD and CM therapy and outlines emerging drug targets in this field.

Mitochondrial Energetics in Normal Cardiac Function

The main function of cardiac mitochondria is ATP synthesis via oxidative phosphorylation (Ox-Phos). After
Mitochondrial Dysfunction in CM

The major cause of acute CM, the precursor to heart failure, is myocardial ischemia (see section Mitochondrial Dysfunction in IHD), whereas less acute forms of CM are idiopathic, inherited, or caused by chronic diseases, such as hypertension and diabetes mellitus. Regardless of the cause, altered mitochondrial bioenergetics appear to play a substantial role in CM.

Under pathological conditions, such as CM, the normal metabolic flexibility of the heart is superseded by activation of a fetal metabolic program, with a preference for glucose over fat as the substrate for Ox-Phos. Although such changes lower the $O_2$ consumed per ATP produced, the yield of ATP per substrate also decreases. Such inefficient metabolism lowers ATP and phosphocreatine levels and decreases metabolic reserve and flexibility. Interestingly, adult hearts that adopt this neonatal metabolism are refractory to protection by ischemic preconditioning (IPC, see section Current Mitochondrial Treatments for CM) like the neonatal heart. However, IPC itself comprises metabolic remodeling, suggesting that altered metabolism may be an adaptive response to ischemia, becoming pathological if the stimulus persists.

Mitochondrial Dysfunction in IHD

The primary pathological event in IHD is acute myocardial infarction (AMI) caused by coronary artery obstruction. Whereas permanent occlusion often results in cardiac remodeling and hypertrophy, transient occlusion is also detrimental to cardiac function, and the reperfusion phase of IR injury is particularly injurious to mitochondria.

A wide spectrum of mitochondrial derangements occurs in the post-IR heart, including the following: (1) Inhibition of respiratory complexes and the adenine nucleotide translocase, (2) Increased proton leak of the inner membrane, (3) Oxidation of the phospholipid cardiolipin and associated membrane protein dysfunction, (4) Excessive generation of reactive oxygen species (ROS), (5) Opening of the permeability transition (PT) pore, and release of cell death–inducing proteins, including cytochrome $c$, (6) Catastrophic nucleotide depletion, and (7) Mitochondrial Ca$^{2+}$ overload. These phenomena are summarized in Figure 1, and while a brief understanding is helpful to understand the mechanisms of protection by mitochondrial therapeutics, in-depth discussions are available elsewhere.

Current Mitochondrial Treatments for CM

Several studies have attempted to treat heart failure associated with CM by targeting bioenergetic dysfunction. The general strategy for primary mitochondrial genetic disorders is supplementation with cofactors, such as coenzyme Q, carnitine, riboflavin, and thiamine, or antioxidants such as ascorbate. The efficacy of such treatments for CM is unclear, because most mitochondrial disease trials have focused on neurological complications of these disorders rather than CM. Several groups have tested the coenzyme Q analog idebenone, and in some studies this molecule slowed or prevented progression of hypertrophic CM in patients with Friedreich’s ataxia (a disease of iron-sulfur cluster assembly that affects the RC), however a more recent trial found no improvement in left ventricle mass or function.

Notably, even in CMs of unknown or nonmitochondrial causes, the mainstay clinical agents are coenzyme Q and carnitine, particularly if carnitine deficiency is evident on blood
testing. Idebenone has also been used for nonmitochondrial CM, and it improved cardiac function in a mouse model of duchenne muscular dystrophy.32 Whereas a subsequent phase II trial in duchenne muscular dystrophy patients failed to show significant improvement in cardiac function, a promising trend was seen and a larger trial is underway.33

Another potential therapy for mitochondrial disorders is dichloroacetate, which stimulates pyruvate dehydrogenase to shunt pyruvate into Ox-Phos. Dichloroacetate has yielded mixed results in treating neurological symptoms of mitochondrial disorders, leading to suggestions that it may only be useful in patients with pyruvate dehydrogenase deficiency.29,34 The ability of dichloroacetate to treat mitochondrial CM has not been tested, but in patients with a mixture of non-ischemic and ischemic dilated CM, dichloroacetate showed mixed effects on myocardial O2 consumption and mechanical efficiency.35,36

The amino acid l-arginine has also been proposed to treat mitochondrial disease, and in patients with mitochondrial CM, arginine increased aerobic metabolism and myocardial efficiency. The mechanism appeared to be independent of myocardial blood flow (ie, arginine as a substrate for NO production), possibly occurring via supplying the tricarboxylic acid cycle with 2-oxyglutarate.37 Another drug of interest is perhexiline, which significantly increased phosphocreatine/ATP ratio, corrected diastolic dysfunction, and increased exercise capacity in CM patients, by inhibiting fatty acid oxidation (FAO) and increasing glucose utilization.38 Other potential metabolic modulators, as well as nonpharmacological therapies, such as exercise training, may prove efficacious in treating CM.5,8 Pharmacological options are discussed further in section Mitochondrial Metabolism.

**Current Mitochondrial Treatments for IHD**

Many therapies are aimed at slowing the progression of IHD, including statins to slow atherosclerotic lesion formation, antianginals to improve flow to transiently ischemic tissue, and antiplatelet agents to impede clotting at plaque rupture. Whereas these agents do impact the incidence of ischemic events, there are limited therapies to protect myocardial function once an ischemic insult occurs. In some situations, cardiac ischemia can be anticipated in advance, such as during cardiac surgery or balloon inflation during PCI. Careful quantification of cardiac damage using biomarkers can allow clinical trials to identify protective strategies. As such, in cardiac surgery, cardioplegia (controlled arrest of the heart, dropping myocardial energy requirements),39
Table. Clinical Development of Mitochondrial Therapies for Cardiomyopathy and Ischemic Heart Disease

<table>
<thead>
<tr>
<th>Agent</th>
<th>Target/MOA</th>
<th>Clinical Development/Usage</th>
<th>Status of Cardiac Clinical Development</th>
<th>Clinical Trial</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT pore inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4′-chlorodiazepam (Ro5-4684)</td>
<td>TSPO</td>
<td>In-use</td>
<td>Phase III (AMI)</td>
<td>NCT01502774</td>
<td>109</td>
</tr>
<tr>
<td>CsA</td>
<td>CypD</td>
<td>In-use (immunosuppression)</td>
<td></td>
<td></td>
<td>100</td>
</tr>
<tr>
<td>Debio025</td>
<td>CypD</td>
<td>Phase II (Hepatitis C)</td>
<td></td>
<td></td>
<td>106</td>
</tr>
<tr>
<td>NIM811</td>
<td>CypD</td>
<td>Phase II (Hepatitis C)</td>
<td></td>
<td></td>
<td>216</td>
</tr>
<tr>
<td>Sanglifehrin A</td>
<td>CypD</td>
<td>Phase II (AMI)</td>
<td></td>
<td></td>
<td>104</td>
</tr>
<tr>
<td>TR040303</td>
<td>TSPO</td>
<td>Phase II (AMI)</td>
<td></td>
<td>NCT01374321</td>
<td>110</td>
</tr>
<tr>
<td>NO analogs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MitoSN01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>120</td>
</tr>
<tr>
<td>Nitrolipids</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>123</td>
</tr>
<tr>
<td>Nitrite</td>
<td></td>
<td>In-use (cyanide antidote)</td>
<td>Phase II (AMI)</td>
<td>NCT01584453</td>
<td>127</td>
</tr>
<tr>
<td>SN0-MPG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>119</td>
</tr>
<tr>
<td>Antioxidants</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edaravone</td>
<td></td>
<td></td>
<td>In-use (stroke, Japan)</td>
<td>Phase IV (AMI)</td>
<td>NCT00265239</td>
</tr>
<tr>
<td>Glutathione</td>
<td></td>
<td></td>
<td>Nutriceutical</td>
<td>Cardioplegia additive</td>
<td>121</td>
</tr>
<tr>
<td>HVTP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>121</td>
</tr>
<tr>
<td>Imz-S₃As</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>153</td>
</tr>
<tr>
<td>Mangafodipir</td>
<td></td>
<td></td>
<td>Phase II (AMI)</td>
<td>NCT00265239</td>
<td></td>
</tr>
<tr>
<td>Melatonin</td>
<td></td>
<td></td>
<td>Nutriceutical</td>
<td>Phase II (AMI)</td>
<td>NCT01172171</td>
</tr>
<tr>
<td>MitoE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>150</td>
</tr>
<tr>
<td>MitoQ</td>
<td></td>
<td>Phase II (Hepatitis C, NASH)</td>
<td></td>
<td></td>
<td>149</td>
</tr>
<tr>
<td>MPG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>82</td>
</tr>
<tr>
<td>SOD, catalase</td>
<td></td>
<td></td>
<td>Various clinical trials</td>
<td></td>
<td>78</td>
</tr>
<tr>
<td>SS31 (beadavalia)</td>
<td></td>
<td></td>
<td>Phase II (AMI)</td>
<td>NCT01572909</td>
<td></td>
</tr>
<tr>
<td>Potassium channel openers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3-NP</td>
<td>mKₓ&lt;sub&gt;ATP&lt;/sub&gt;</td>
<td></td>
<td></td>
<td></td>
<td>152</td>
</tr>
<tr>
<td>Atpenin A5</td>
<td>mKₓ&lt;sub&gt;ATP&lt;/sub&gt;</td>
<td></td>
<td></td>
<td></td>
<td>143</td>
</tr>
<tr>
<td>Cromakalim</td>
<td>mKₓ&lt;sub&gt;ATP&lt;/sub&gt;</td>
<td></td>
<td></td>
<td></td>
<td>134</td>
</tr>
<tr>
<td>BMS-191095</td>
<td>mKₓ&lt;sub&gt;ATP&lt;/sub&gt;</td>
<td></td>
<td></td>
<td></td>
<td>135</td>
</tr>
<tr>
<td>Diazoxide</td>
<td>mKₓ&lt;sub&gt;ATP&lt;/sub&gt;</td>
<td></td>
<td>Various clinical trials</td>
<td></td>
<td>132</td>
</tr>
<tr>
<td>Malonate</td>
<td>mKₓ&lt;sub&gt;ATP&lt;/sub&gt;</td>
<td></td>
<td>Phase II (osteoporosis)</td>
<td></td>
<td>139</td>
</tr>
<tr>
<td>Minoxidil</td>
<td>mKₓ&lt;sub&gt;ATP&lt;/sub&gt;</td>
<td></td>
<td>In-use (hypertension, alopecia)</td>
<td></td>
<td>138</td>
</tr>
<tr>
<td>NS11021</td>
<td>mBK</td>
<td></td>
<td></td>
<td></td>
<td>143</td>
</tr>
<tr>
<td>NS1619</td>
<td>mBK</td>
<td></td>
<td></td>
<td></td>
<td>145</td>
</tr>
<tr>
<td>Pinacidil</td>
<td>mKₓ&lt;sub&gt;ATP&lt;/sub&gt;</td>
<td></td>
<td>In-use (hypertension)</td>
<td></td>
<td>134</td>
</tr>
<tr>
<td>Respiratory chain inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amobarbital</td>
<td>Complex I</td>
<td></td>
<td>In-use (anxiety, sedation)</td>
<td></td>
<td>155</td>
</tr>
<tr>
<td>Antimycin A</td>
<td>Complex III</td>
<td></td>
<td></td>
<td></td>
<td>156</td>
</tr>
<tr>
<td>H₂S</td>
<td>Complex IV</td>
<td></td>
<td>Phase I (renal function)</td>
<td></td>
<td>158</td>
</tr>
<tr>
<td>Rotenone</td>
<td>Complex I</td>
<td></td>
<td></td>
<td></td>
<td>154</td>
</tr>
<tr>
<td>RISK pathway modulators</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lithium</td>
<td></td>
<td></td>
<td>In-use (bipolar disorder)</td>
<td></td>
<td>164</td>
</tr>
<tr>
<td>SB216763</td>
<td>GSK3-β</td>
<td></td>
<td></td>
<td></td>
<td>165</td>
</tr>
<tr>
<td>Statins</td>
<td>HMG-CoA reductase</td>
<td></td>
<td>In-use (hyperlipidemia)</td>
<td>Completed phase IV (AMI)</td>
<td>172</td>
</tr>
<tr>
<td>Aldehyde dehydrogenase  2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>α-Lipoic acid</td>
<td></td>
<td></td>
<td>Nutriceutical</td>
<td></td>
<td>177</td>
</tr>
<tr>
<td>Alda1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>178</td>
</tr>
</tbody>
</table>

(continued)
hypothermia,\textsuperscript{40} \(\beta\) blockers,\textsuperscript{41} and tight glycemic control\textsuperscript{42} are all currently used for cardioprotection.

Recently, protecting the heart with IPC has begun to translate into the clinic.\textsuperscript{43} In this method, short intermittent IR cycles are administered before index ischemia, yielding reduced infarct size and improved postischemic function. IPC has completed successful clinical trials in both PCI and cardiac surgery, however it is usually accomplished by repeatedly cross-clamping the aorta, which may increase the risk of cerebral emboli or aortic vascular damage.\textsuperscript{44} In this regard, it is notable that transient occlusion at sites remote from the heart (remote ischemic preconditioning) is also cardioprotective,\textsuperscript{45} with clinical studies showing remote ischemic preconditioning efficacy in cardiac and noncardiac surgery\textsuperscript{46,47} and PCI.\textsuperscript{48} However, failure of other remote ischemic preconditioning trials suggests protocol optimization may be required.\textsuperscript{49} As shown in Figure 2, the mechanism of IPC protection is incredibly complex, with mitochondria (and particularly mitochondrial K+ channels, see section Mitochondrial Potassium Channels) playing a key role.\textsuperscript{50,51}

### Table. Continued

<table>
<thead>
<tr>
<th>Agent</th>
<th>Target/MOA</th>
<th>Clinical Development/Usage</th>
<th>Status of Cardiac Clinical Development</th>
<th>Clinical Trial</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolic modulators</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A-769662</td>
<td>AMPK</td>
<td></td>
<td>Failed phase III (MI)</td>
<td>NCT00872001</td>
<td>206</td>
</tr>
<tr>
<td>Acadesine (AICAR)</td>
<td>AMPK, nonspecific</td>
<td>Nutriceutical</td>
<td>Various clinical trials (CM)</td>
<td></td>
<td>74</td>
</tr>
<tr>
<td>Cofactors (carnitine, Co-Q etc)</td>
<td>Pyruvate dehydrogenase</td>
<td>Failed clinical trials for lactic acidosis, MELAS, Multiple trials in cancer.</td>
<td></td>
<td></td>
<td>38</td>
</tr>
<tr>
<td>DCA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etomoxir</td>
<td>CPT1</td>
<td></td>
<td></td>
<td></td>
<td>108</td>
</tr>
<tr>
<td>GIK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>102</td>
</tr>
<tr>
<td>Idebenone</td>
<td>Respiratory chain</td>
<td></td>
<td>Phase III (DMO)</td>
<td>NCT01027884</td>
<td>30</td>
</tr>
<tr>
<td>L-Arginine</td>
<td>NOS and TCA cycle substrate</td>
<td></td>
<td></td>
<td></td>
<td>37</td>
</tr>
<tr>
<td>Oxenicine</td>
<td>CPT1</td>
<td></td>
<td></td>
<td></td>
<td>109</td>
</tr>
<tr>
<td>Perhexiline</td>
<td>CPT1</td>
<td></td>
<td></td>
<td></td>
<td>38</td>
</tr>
<tr>
<td>Ranolazine</td>
<td>Late Na(^+) channel, specific target in-use (angina)</td>
<td></td>
<td>Failed phase III (AMI)/Phase IV (PCI)</td>
<td>NCT0099788</td>
<td>200</td>
</tr>
<tr>
<td>Trimetazidine</td>
<td>Late Na(^+) channel, specific target in-use (angina)</td>
<td></td>
<td></td>
<td></td>
<td>121</td>
</tr>
<tr>
<td>Other</td>
<td>Adenosine</td>
<td></td>
<td></td>
<td></td>
<td>65</td>
</tr>
<tr>
<td>AMP579</td>
<td>Adenosine receptors</td>
<td></td>
<td>Failed clinical trials (MI, CABG)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anesthetic preconditioning</td>
<td>Adenosine receptors</td>
<td></td>
<td>Failed phase III (MI)</td>
<td>ADMIRE I &amp; II</td>
<td>68</td>
</tr>
<tr>
<td>(\beta)-blockers</td>
<td>(\beta)-adrenergic receptors</td>
<td>In-use (patients at risk of MI)</td>
<td></td>
<td></td>
<td>52,53</td>
</tr>
<tr>
<td>Cloxyquin/clioquinol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>61</td>
</tr>
<tr>
<td>Hypertension</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>170</td>
</tr>
<tr>
<td>Melcitine</td>
<td>Histamine receptors</td>
<td>In-use (antihistamine)</td>
<td></td>
<td></td>
<td>40</td>
</tr>
<tr>
<td>Preconditioning (IPC, IPoC, RIPC)</td>
<td></td>
<td></td>
<td>Multiple clinical trials</td>
<td></td>
<td>214</td>
</tr>
</tbody>
</table>

MOA indicates mechanism of action; TSPO, translocator protein; CyP2D, cyclophilin D; NCT, National Clinical Trial; MPG, mercaptoypyronyl glycine; MI, myocardial infarction; AMI, acute myocardial infarction; DCA, dichloroacetate; MELAS, mitochondrial encephalopathy lactic acidosis and stroke-like episodes; GIK, glucose-insulin-potassium; Mitof, mitochondrially targeted coenzyme Q; CoA, cyclophilin A; SNO-MPG, S-nitroso mercaptoypyronyl glycine; NASH: nonalcoholic steatohepatitis; NOS, NO synthase; 3-NP, 3-nitropropionic acid; RIPC, remote ischemic preconditioning; TCA, tricarboxylic acid; HVTP, 2-hydroxylamine-vinyl-TPP\textsuperscript{+}; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; DMD, duchenne muscular dystrophy; CPT, carnitine palmitoyltransferase; GSK-3\(\beta\), glycogen synthase kinase-3\(\beta\); HMG-CoA, 3-hydroxy-3-methyl-glutaryl-coenzyme; AMPK, AMPK-dependent protein kinase; IPC, ischemic preconditioning; IPoC, ischemic postconditioning; mK\(_{ATP}\), mitochondrial ATP sensitive K\(^+\) channel; SOD, superoxide dismutase; mBK, mitochondrial BK.

Related to IPC, and more clinically tractable, is volatile anesthetic preconditioning (APC), in which halogenated anesthetics (iso-/des-/sevo-flurane) are known to activate many of the same intracellular signaling events as IPC.\textsuperscript{52,53} APC is also thought to open mitochondrial K\(^+\) channels (see section Mitochondrial Potassium Channels). Unfortunately, the unanticipated nature of AMI makes it difficult to offer protection by preconditioning, and the current standard of care is early reperfusion via PCI.
Emerging Mitochondrial Therapeutic Targets

Despite the wave of failed CM and IHD candidate therapeutics to date, the mitochondrial research community has made significant strides in deciphering mechanisms of cardioprotection (Figure 2), resulting in development of more specific and rational approaches to mitochondrial therapeutics. This includes the identification of novel targets and the development of promising therapeutics that are currently in clinical trials. These approaches are aimed at modulating key biological processes that contribute to cardioprotection, such as mitochondrial metabolism, energy production, and signaling pathways. The development of these therapies is a testament to the growing understanding of the complex interplay between mitochondrial function and cardiac health. Further research will be essential to validate these findings and to advance the clinical utility of these novel approaches.
targeted molecules. Some of these newer candidates are discussed below, categorized by the mitochondrial phenomena which they target.

**Mitochondrial Permeability Transition Pore**

Opening of the mitochondrial PT pore is a major driver of necrotic cell death in IR injury. The identity of the molecules that assemble to form the PT pore remains somewhat controversial, however transgenic models have demonstrated PT pore regulation by the adenine nucleotide translocase, the phosphate carrier, and cyclophilin D (CypD), with the role of the voltage-dependent anion channel less clear. Other proteins implicated in the PT pore or its regulation include hexokinase II, which links the pore to cellular metabolism, and mitochondrial translocator protein, which interacts with voltage-dependent anion channel. Drugs targeting these PT pore components are candidates for cardioprotective therapeutics.

The first drug shown to inhibit PT pore opening was cyclosporine A (CsA), which binds to CypD. CsA protects against IR injury in myocytes and intact hearts, and a pilot clinical trial demonstrated 20% infarct reduction with CsA administration before PCI in myocardial infarction patients, with benefits still evident 6 months later. A phase III trial (NCT01502774) is currently underway. Notably, CsA is also used for immunosuppression after organ transplant, mediated by its binding to calcineurin. Calcineurin is also a well-known hypertrophic signaling molecule, and hypertrophy attributed to CsA usage has been reported in transplant patients. Thus, CypD-specific CsA analogs have been developed, including sanglifehrin A, Debi025, and Debi025 [NCT00537407 and NCT00854802] and NIM811 [NCT00983060] are in clinical trials for hepatitis C. These molecules are cardioprotective in animal models of IR injury, although none has yet progressed to clinical trials. A mitochondria-targeted CsA has also been developed, exhibiting higher potency and improved CypD affinity. The translocator protein ligands SSR180575, 4′-chlorodiazepam (Ro5-4684), and TRO40303 were also shown to reduce IR injury in various cell and animal models, and TRO40303 is entering clinical trials (NCT01374321).

**NO-Based Mitochondrial Therapies**

The role of NO in both endogenous cardioprotection and in mediating protective effects of drugs has been reviewed extensively elsewhere. In addition to classic NO signaling via cGMP/cGMP-dependent protein kinase, which feeds into reperfusion injury salvage kinase (RISK) signaling (see section RISK Pathway), nonclassic functions of NO are also implicated in cardioprotection, including protein S-nitrosation, and the generation of nitro-lipids, which are generated endogenously inside mitochondria during IPC, and when added exogenously they protect in various models of IR injury. Such protection occurred via covalent modification of adenine nucleotide translocase, eliciting a mild increase in mitochondrial uncoupling, which is known to confer cardioprotection. Nitro-lipid derivatives are currently in early stage clinical development.

Finally, significant attention has recently focused on the anti-ischemic properties of nitrite (NO2−). Several studies have implicated mitochondria, and in particular complex I, as a downstream target of NO2− in cardioprotection. Injectable sodium NO2− is federal drug administration approved as a cyanide poisoning antidote, and several NO2− clinical trials are underway for cardiac ischemia (NCT01401517, NCT00924118, NCT01098409).

**Mitochondrial Potassium Channels**

The mitochondrial inner membrane contains numerous ion channels, and many studies have suggested a role for mitochondrial K+ channels in cardioprotection. The mechanism of such protection is unclear, and may involve mild uncoupling, diminishing the mitochondrial membrane potential driving force for Ca2+ overload and ROS generation (see section Mitochondrial Dysfunction in Ischemic Heart Disease). Mild swelling associated with mitochondrial K+ influx may also regulate the PT pore.

A mitochondrial KATP channel (mKATP) is reported to play a critical role in cardioprotection by IPC. One of the most widely tested mKATP openers is diazoxide, which has demonstrated protection from IR injury in multiple cell and animal models. Two small clinical trials in CABG patients reported cardioprotection in patients pretreated with diazoxide or undergoing surgery supported by diazoxide-supplemented cardioplegia. Other mKATP openers, including BMS-191095, pinacidil, cromakalim, minoxidil, and nicorandil (Nicorandil failed in phase III clinical trials of acute MI [J-WIND]) are cardioprotective in animal models.

Although the molecular identity of mKATP is unclear, a link exists between respiratory complex II and mKATP such that mKATP openers inhibit complex II, and complex II inhibitors open mKATP. It is hoped that definitive identification of this channel will aid in the design of mKATP specific drugs. Notably, many pharmaceuticals, including fluoxetine, and
some sulfonylureas inhibit mK_{ATP} abrogating cardioprotection by IPC.\textsuperscript{140,141}

In addition to mK_{ATP}, mitochondria are also thought to contain a large conductance K\textsuperscript+ channel (BK) encoded by the SLO gene family,\textsuperscript{142} which is implicated in cardioprotection by APC.\textsuperscript{143} Until recently, consensus held that the mitochondrial BK channel was the SLO1 isoform, based on cardioprotection by the SLO1 opener NS1619 in animal models of IR injury.\textsuperscript{144} However, NS1619 acts on several ion channels\textsuperscript{145,146} and other mitochondrial targets.\textsuperscript{147} A more specific SLO1 activator (NS11021) is also cardioprotective,\textsuperscript{149} but controversy remains because it was recently shown in Caenorhabditis elegans and mice that SLO1 is dispensable for APC, and SLO2 is necessary for APC in the worm.\textsuperscript{139} There are currently no SLO2 specific activators, but SLO2 may be a future therapeutic target.

### Mitochondrial Antioxidants

As discussed in section Current Mitochondrial Treatments for Ischemic Heart Disease, multiple generic nontargeted antioxidants have been clinically unsuccessful in preventing IR injury, although several newer antioxidants are in clinical trials, including melatonin (NCT01172171), mangafodipir (NCT00966563), and edaravone (NCT00265239). In addition, a potentially novel therapeutic approach is the targeting of antioxidants to mitochondria.

A key chemical strategy for mitochondrial targeting is the TPP\textsuperscript+ moiety (see section NO-Based Mitochondrial Therapies). First exploited in the 1970s as a method to measure mitochondrial membrane potential,\textsuperscript{148} several TPP\textsuperscript+-conjugated antioxidants were developed the 1990s. The most prominent of these, mitochondrially targeted coenzyme Q, was cardioprotective in a rat model of IR injury,\textsuperscript{149} and is being developed clinically for other indications (NCT00433108). Other antioxidants conjugated to TPP\textsuperscript+ include α-tocopherol (MitoE) and nitroxides.\textsuperscript{150} As discussed in section NO-Based Mitochondrial Therapies, a TPP\textsuperscript+-conjugated NO\textsuperscript{•} donor confers potent cardioprotection.

Somewhat related to TPP\textsuperscript+ conjugates are the Szeto Schiller peptides, which contain positively charged amino acids and a dimethyl tyrosine residue. Originally developed as opioid peptide analogs, after the discovery they were cardioprotective,\textsuperscript{151} their mechanism was assigned to a mitochondrial antioxidant activity.\textsuperscript{152} The lead compound in this series, Szeto Schiller-31 (α-Arg-dimethyl tyrosine-Asn-Phe-NH\textsubscript{2}), has been renamed Bendavia and is in clinical trials for AMI (NCT01577290).

Bioactivation is another strategy to target drugs to mitochondria, an example being the α-(1-methyl-1H-imidazol-2-ylthio) alkanoic acids. These inactive prodrugs are metabolized by fatty acid β-oxidation in the mitochondrial matrix to reveal a methimizole antioxidant.\textsuperscript{153} α-(1-methyl-1H-imidazol-2-ylthio) alkanoic acids were shown to protect isolated cardiomyocytes from IR injury, in a manner inhibited by the β-oxidation blocker etomoxir. Such molecules may be particularly efficacious in the heart, given its preference for fatty acids as a metabolic substrate (see section Introduction).

### RC Inhibitors

Ischemia inhibits Ox-Phos because of lack of O\textsubscript{2} as the terminal electron acceptor for the RC. Thus, it is somewhat paradoxical that many chemical RC inhibitors are protective in ischemia. This includes inhibitors of complex I (rotenone,\textsuperscript{154} amobarbital,\textsuperscript{155} S-nitrosothiols, NO\textsuperscript{•}), complex II (diazoxx,\textsuperscript{131} atpenin A5\textsuperscript{140}), complex III (antimycin A\textsuperscript{156}), and complex IV (CO,\textsuperscript{157} H\textsubscript{2}S,\textsuperscript{158} NO\textsuperscript{•}). The mechanism of protection may involve inhibition of the large burst of ROS generation and Ca\textsuperscript{2+} overload that occurs at reperfusion, with inhibitor washout allowing a more gradual reintroduction of electron flux to the RC, somewhat akin to ItoC or slow reperfusion.\textsuperscript{159} Although neurological side effects associated with RC inhibitors (eg, Parkinson disease for rotenone, Huntington disease for 3-nitropropionic acid) may preclude their clinical applicability, amobarbital is clinically available and is protective when delivered at reperfusion.\textsuperscript{155}

Related to RC inhibitors, mild uncoupling of Ox-Phos by chemicals such as carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone can also elicit cardioprotection. The mechanism underlying this is unclear but may include inhibition of ROS generation and Ca\textsuperscript{2+} overload.\textsuperscript{124,160} As discussed in section NO-Based Mitochondrial Therapies, cardioprotection by nitro-lipids may also proceed via mild uncoupling.

### RISK Pathway

In IR injury, the PT pore remains closed during ischemia and opens early in reperfusion (Figure 1).\textsuperscript{25} Opening of the pore at reperfusion is regulated by the RISK signaling pathway.\textsuperscript{161} This pathway is implicated in IPC and ItoC\textsuperscript{162} and involves numerous kinases that converge on phosphorylation and inhibition of glycogen synthase kinase-3β,\textsuperscript{163} which is thought to phosphorylate PT pore components (Figure 2).\textsuperscript{164} The glycogen synthase kinase-3β inhibitors SB-216763 and lithium improve post-IR cardiac function in animal models\textsuperscript{164} (although mK\textsubscript{ATP} channels may also be involved\textsuperscript{165}).

Many extracellular signals (eg, insulin\textsuperscript{166}) can activate RISK signaling via receptors, and NO\textsuperscript{•} is also implicated in RISK signaling.\textsuperscript{167,168} Several drugs also exert cardioprotective effects by activating RISK, most notably statins (simvastatin,\textsuperscript{169} mevastatin,\textsuperscript{170} atorvastatin\textsuperscript{71}) via a mechanism not linked to cholesterol lowering. Multiple clinical trials (ARYMDA, NAPLES) and a meta-analysis\textsuperscript{172} have demonstrated cardioprotection with statin administration before emergent PCI. Further clinical trials are ongoing to deliver statins at reperfusion for patients presenting with myocardial infarction (NCT01050348, NCT01334671, NCT00772564). Many other drugs that activate RISK signaling are reviewed elsewhere.\textsuperscript{173,174}

### Aldehyde Dehydrogenase 2

A relatively new target for mitochondrial protection in IR injury is aldehyde dehydrogenase isoform 2 (ALDH2), a mitochondrial enzyme which removes toxic aldehydes, such as 4-hydroxy-2-nonenal. 4-hydroxy-2-nonenal has been implicated in cardiac IR injury, and can inhibit metabolic enzymes and RC complexes, and open the PT pore.\textsuperscript{175}

Overexpression of ALDH2 decreases 4-hydroxy-2-nonenal levels, yielding decreased infarct size and increased...
postischemic function. Furthermore, Alda 1, a small molecule ALDH2 activator, decreases infarct size in animal models of IR injury. Recently α-lipoic acid, a cofactor for ALDH2, has shown cardioprotection in an ALDH2 dependent fashion and is currently in clinical trials for several conditions, including diabetes mellitus (NCT00398892) and atherosclerosis (NCT00765310). In addition, ALDH2 activation may be capable of delivering cardioprotection in conditions where other drugs have failed, including diabetes mellitus and nitrate tolerance. The latter is a major clinical problem, as patients taking nitrates are often at risk for MI.

Mitochondrial Metabolism

One of the earliest methods to improve mitochondrial metabolism in IR was the use of glucose-insulin-potassium (GIK) supplementation. In addition to GIK, insulin alone can drive both glucose and fatty acids into the cell to support metabolism. GIK has shown mixed results in CABG surgery, with a recent meta-analysis showing no improvement in the incidence of arrhythmia or mortality. However, with recent emphasis on tight glucose control during cardiac surgery, many patients receive intraoperative GIK anyway. Results in AMI have been consistently negative, although a recent trial (NCT00091507) of GIK delivery by emergency personnel in the prehospital setting yielded a 50% drop in in-hospital cardiac arrest and mortality.

FAO is also an attractive drug target in ischemia, because it uses more O₂ per ATP produced (versus glucose). During IR injury, catecholamine-induced increases in serum fatty acid levels may enhance FAO, and indeed reperfusion with fatty acid free serum is cardioprotective. Inhibitors of carnitine palmitoyltransferase 1 inhibitor, perhexiline, corrected diastolic dysfunction, and increased exercise capacity in heart failure demonstrated improved ventricular function, but no protection of IR injury. Another carnitine palmitoyltransferase 1 inhibitor, perhexiline, corrected diabetic dysfunction, and increased exercise capacity in patients with hypertrophic CM. Oxefinone shows similar effects but is not used in humans.

Other drugs that inhibit FAO are the antianginals trimetazidine and ranolazine. A meta-analysis of trimetazidine in heart failure demonstrated improved ventricular function and decreased mortality, cardiovascular events, and hospitalizations. In IR injury it exhibited mixed results in both animal models and clinical trials, demonstrating protection when administered before CABG, but no protection in AMI except for a cohort of patients who did not receive thrombolysis. Ranolazine is reported to shift cell metabolism from FAO toward glycolysis, although it may also have effects on cellular Na⁺ and Ca²⁺ homeostasis or protection of complex I. In animal models of heart failure ranolazine reduced diastolic dysfunction and improved left ventricle efficiency, and in IR injury it decreased both infarct size and cardiac enzyme release and improved postischemic ventricular function. Clinical trials confirmed its efficacy in treating angina but showed no protection in AMI. Further ranolazine trials are in development for PCI (NCT01491061). Despite the consensus that fatty acids are toxic to the ischemic heart, it is notable that carnitine supplementation is paradoxically cardioprotective in animal models of IR injury. In clinical trials, carnitine prevented left ventricular remodeling after ST segment elevation myocardial infarction (CEDIM-I) and reduced 5-day mortality, however this mortality benefit was nonsignificant at 6 months (CEDIM-II).

Global regulators of metabolism may also be therapeutic targets in IHD. An example is AMP-dependent protein kinase, which upregulates both FAO and glucose utilization in response to decreased ATP levels. Whether increased AMP-dependent protein kinase is helpful or harmful to myocardium after IR injury is still unclear. The AMP-dependent protein kinase specific activator A-769662 is cardioprotective during IR injury, but activators such as acadesine or metformin may have nonspecific effects. Another important metabolic regulator is silent information regulator 2 P homolog 1 (SIRT1), which is required for cardioprotection by acute IPC. Despite controversy regarding the SIRT1 activator resveratrol, SIRT1 activators are in clinical development.

Similarly, SIRT3, which is located in the mitochondria, has also emerged as an important metabolic regulator known to deacetylate numerous mitochondrial proteins involved in FAO and Ox-Phos. Notably a mitochondrial acetyltransferase (GCN5L1) that is counterpart to SIRT3 has recently been described, although from a pharmacological standpoint, specific drugs that target mitochondrial SIRT3 (versus other SIRTs) have not yet been developed. Finally, it has recently emerged that mitophagy, the process by which damaged mitochondria are removed and recycled, is an important player not only in metabolic homeostasis, but is also critical for IPC.

Conclusions and Future Directions

In summary, despite numerous failures in clinical development of drugs to treat IHD and CM, the pipelines of several companies still contain IHD and CM drugs, and many of these therapies appear targeted at mitochondria. Coupled with novel compounds which have not yet reached clinical trials, these are exciting times to be involved in drug development for these debilitating conditions. However, it should be emphasized that, despite the large number of mitochondrial drugs discussed in section Emerging Mitochondrial Therapeutic Targets, there is no guarantee that these molecules will be more efficacious in the clinic than those tested to date. Many of the same reasons that have been invoked to explain previous clinical failures also apply to these therapeutic candidates.

In addition to the novel compounds discussed, other significant developments also deserve brief mention. The first is National Institutes of Health consortium for preclinicalAssessment of Cardioprotective therapies (CAESAR), an National Institutes of Health-sponsored consortium which aims to bridge the gap between preclinical and clinical trials for promising cardioprotective therapies. By adopting standardized IR protocols in several animal models, and using practices common to clinical trials (double blinding, multiple centers, placebo controls), the consortium aims to put only the most promising therapies forward into human clinical trials. This will clearly be a valuable tool for researchers in the field.
Secondly, with a few exceptions, high-throughput screening has been underused as a drug development approach for IHD and CM. This may be because clinically relevant models of IR injury often use animals and are time-consuming and expensive (ie, not amenable to high-throughput screening), whereas high-throughput screening-ready IR models may not be physiologically relevant. In a recent screen for molecules that alter cell metabolism, it was hypothesized that hits that promote glycolysis would be beneficial during ischemia, and indeed one such molecule (meclizine) was protective in heart failure. In another recent screen, we developed an IR injury model using a 24-well metabolic phenotyping device, with post-IR cell death and metabolism as end points. One hit from the screen was cloxyquin, which was first proposed as an antiischemic agent. However, whereas high-throughput screening-ready IR models may not be expensive (ie, not amenable to high-throughput screening), screening-ready IR models may not be expensive (ie, not amenable to high-throughput screening). The role of mitochondrial substrates and metabolic pathways in the treatment of mitochondrial disorders is currently under investigation.

**Sources of Funding**

P.S.B. is funded by grants from the US National Institutes of Health (HL-071158, GM-087483). A.M.W. is supported by a grant from the University of Rochester Clinical Translational Sciences Institute (HL-071158, GM-087483). A.M.W. is supported by a grant from the American Heart Association and the Children’s Cardiomyopathy Foundation.

**Disclosures**

None.

**References**


36. Lewis JF, DaCosta M, Wargowich T, Staquepoole P. Effects of dichlo-

37. Arakawa K, Kado T, Ikawa M, Morikawa N, Kawai Y, Sahashi K, Lee JG, Kuriyama M, Miyamoto I, Okazawa H, Yoneda M. Abnormal myo-


1234 Circulation Research
October 12, 2012


Kukreja RC. Synergistic effects of atrorvastatin and sildenafil in cardioprotection-role of NO. Cardiovascular Drugs Ther. 2006;20:5–8.


Bell RM, Yellon DM. Atofarnat, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol. 2003;41:508–515.


Mitochondria as a Drug Target in Ischemic Heart Disease and Cardiomyopathy
Andrew M. Walters, George A. Porter, Jr and Paul S. Brookes

Circ Res. 2012;111:1222-1236
doi: 10.1161/CIRCRESAHA.112.265660
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2012 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circres.ahajournals.org/content/111/9/1222

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in
Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the
Editorial Office. Once the online version of the published article for which permission is being requested is located,
click Request Permissions in the middle column of the Web page under Services. Further information about this
process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/